跳至主要内容
临床试验/JPRN-jRCT1092220327
JPRN-jRCT1092220327已完成Unknown

Treatment of severe acute respiratory failure patients requiring Extracorporeal Membrane Oxygenation (ECMO)Study protocol No.: MJ-CP042-01-01 - MJ-CP042-01-01

Getinge Group Japan K.K.0 个研究点目标入组 20 人开始时间: 2018年2月1日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 < 75age old(—)
性别
All

入选标准

  • 1.Patients who are able to provide written consent to participate in the study
  • 2.Ages between 20 and 75 years old; no gender restriction
  • 3.Longer than 6 hours of ECMO therapy is expected
  • 4.Meets at least one of the 3 criteria below:
  • -FiO2 >0.8, PFR<100mmHg, PEEP>=10cmH2O
  • -Uncompensated hypercapnia (PaCO2 >80mmHg) in spite of PIP>=30cmH2O
  • -Serious air leak syndrome

排除标准

  • 1.Cause of the severe respiratory failure is determined to be irreversible respiratory disease
  • 2.Remaining on high ventilator settings (FiO2 >0.9, PIP >30cmH2O) for more than 7 days
  • 3.Serious immunodeficiency (Neu<400mm3)
  • 4.Pre-existing conditions (central nervous system disorder, end-stage malignancy, systemic bleeding risk due to ECLS anticoagulation) which may have significant impact on QOL
  • 5.Severe aortic valve insufficiency in the case of VA circulation
  • 6.Patients with known hypersensitivity to heparin
  • 7.Patients currently suffering from, or with a history of type II antibody-related, heparin-induced thrombocytopenia (HIT)
  • 8.Pregnant or possibility of pregnancy
  • 9.Participating in another clinical trial or Postmarketing clinical study
  • 10.Those patients determined by the investigator to be inappropriate to participate in the trial

研究者

发起方
Getinge Group Japan K.K.

相似试验